Application note: Synthesis confirmation for nucleic acid medicines – rapid sequence confirmation using a MALDI-TOF mass spectrometer
Posted: 14 December 2020 | Shimadzu | No comments yet
Medicines that utilise nucleic acids, such as DNA and RNA which control genetic information, are called “nucleic acid medicines”.
They allow targeting of molecules such as messenger RNA (mRNA) and micro RNA (miRNA) that cannot be targeted with traditional low molecular weight drugs and antibody medicines. Nucleic acid medicines are innovative next-generation pharmaceuticals that could be used for the treatment of genetic disorders that have thus far been difficult to treat.
Related content from this organisation
- Application note: Highly efficient method development using LC-MS for automated peak tracking
- Application note: Highly efficient method development for analysis of oligonucleotides
- Application note: Analysis of voglibose by postcolumn derivatisation method
- Application note: Comprehensive fractionation of herbal medicine components by PDA-ELSD-triggered preparative LC
- Application Notes Supplement 2021